BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31694013)

  • 1. Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression.
    Bremer SCB; Conradi LC; Mechie NC; Amanzada A; Mavropoulou E; Kitz J; Ghadimi M; Ellenrieder V; Ströbel P; Hessmann E; Gaedcke J; Bohnenberger H
    Digestion; 2021; 102(2):227-235. PubMed ID: 31694013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
    Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer.
    Ishikawa S; Hayashi H; Kinoshita K; Abe M; Kuroki H; Tokunaga R; Tomiyasu S; Tanaka H; Sugita H; Arita T; Yagi Y; Watanabe M; Hirota M; Baba H
    Int J Cancer; 2014 Dec; 135(11):2528-36. PubMed ID: 24346863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the expression of claudin 23 by the enhancer of zeste 2 polycomb group protein in colorectal cancer.
    Maryan N; Statkiewicz M; Mikula M; Goryca K; Paziewska A; Strzałkowska A; Dabrowska M; Bujko M; Ostrowski J
    Mol Med Rep; 2015 Jul; 12(1):728-36. PubMed ID: 25695204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis.
    Liu Y; Liu T; Bao X; He M; Li L; Yang X
    Int J Gynecol Pathol; 2014 May; 33(3):218-24. PubMed ID: 24681730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro.
    He SB; Zhou H; Zhou J; Zhou GQ; Han T; Wan DW; Gu W; Gao L; Zhang Y; Xue XF; Zhang LF; Fei M; Hu SQ; Yang XD; Zhu XG; Wang L; Li DC
    Exp Biol Med (Maywood); 2015 Apr; 240(4):458-66. PubMed ID: 25005166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The noncanonical role of EZH2 in cancer.
    Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
    Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
    Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
    Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
    Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
    J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
    Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
    BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway.
    Kurihara H; Maruyama R; Ishiguro K; Kanno S; Yamamoto I; Ishigami K; Mitsuhashi K; Igarashi H; Ito M; Tanuma T; Sukawa Y; Okita K; Hasegawa T; Imai K; Yamamoto H; Shinomura Y; Nosho K
    Oncotarget; 2016 Mar; 7(11):12704-17. PubMed ID: 26871294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.
    Nouruzi S; Tabrizian N; Zoubeidi A
    Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
    Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
    Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hotair mediates tumorigenesis through recruiting EZH2 in colorectal cancer.
    Huang KB; Zhang SP; Zhu YJ; Guo CH; Yang M; Liu J; Xia LG; Zhang JF
    J Cell Biochem; 2019 Apr; 120(4):6071-6077. PubMed ID: 30362162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.